The present invention relates to a method of quantifying methane removal in the atmosphere. Specifically, the present invention relates to quantifying methane removal by iron-salt aerosols. The present invention also relates to the method for use for the purpose of claiming a carbon credit.
The present invention relates to isolated polypeptides derived from stanniocalcin-2 (STC2), and polypeptide fragments and variants thereof useful for inhibiting proteolytic activity of the pregnancy-associated plasma protein-A (PAPP-A), as well as methods for identifying ligands and inhibitors of PAPP-A.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (USA)
UNIVERSITY OF COPENHAGEN (Danemark)
Inventeur(s)
Flood, Amar H.
Yadav, Ravindra Kumar
Satapathy, Sitakanta
Deshmukh, Prathmesh
Menon, Vinod
Laursen, Bo
Abrégé
Disclosed herein is a microcavity comprising a photoluminescent material positioned between two reflectors, wherein the photoluminescent material comprises a cationic molecular dye, a macrocyclic anion receptor host, and an anion embedded within the macrocyclic anion receptor host and methods of making and using the same.
C07C 255/49 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné
C07C 255/58 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné contenant des groupes cyano et des atomes d'azote, liés par des liaisons simples et n'étant pas liés de plus à d'autres hétéro-atomes, liés au squelette carboné
C07D 209/56 - Systèmes cycliques contenant au moins trois cycles
H10K 85/60 - Composés organiques à faible poids moléculaire
H10K 50/11 - OLED ou diodes électroluminescentes polymères [PLED] caractérisées par les couches électroluminescentes [EL]
4.
CHLORIDE ION ADSORBENT AND METHOD OF PRODUCING HYDROGEN DIRECTLY FROM SEAWATER USING SAME ADSORBENT
INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (République de Corée)
UNIVERSITY OF COPENHAGEN (Danemark)
Inventeur(s)
Na, Kyung Su
Choi, Yu Yeol
Lee, Ji Woong
Milia, Marco
Abrégé
22) is inhibited by the chloride ion adsorbent while producing hydrogen without treating seawater to freshwater. In the absence of the chloride ion adsorbent, otherwise, a large amount of chloride ions (Cl-) will be oxidized during electrolysis due to NaCl dissolved in a large amount in seawater.
B01J 20/10 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant de la silice ou un silicate
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
C25B 1/04 - Hydrogène ou oxygène par électrolyse de l'eau
5.
STENCIL MASK AND USE THEREOF IN LITHOGRAPHY FABRICATION
The disclosure relates to a stencil mask, a method for manufacturing the stencil mask and use of the stencil mask in nanoscale device nanofabrication, including imprinting on substrates of deposition patterns for nanoscale devices. One embodiment relates to a stencil mask for manufacturing at least one nanoscale device on a substrate, the stencil mask comprising, a membrane having a top surface and bottom surface and a thickness therebetween of at least 500 nm, a predefined pattern of apertures extending through the membrane, each aperture having a width and a length in the top surface of the membrane, wherein at least the width and/or the length of one of said apertures is of less than 100 nm, each aperture defined by inner sidewalls extending between the top surface and the bottom surface of the membrane, and a set of separating nanostructures on the top surface of the membrane for separating the top surface of the membrane from a top surface of the substrate.
G03F 1/20 - Masques ou masques vierges d'imagerie par rayonnement d'un faisceau de particules chargées [CPB charged particle beam], p.ex. par faisceau d'électrons; Leur préparation
C23C 14/04 - Revêtement de parties déterminées de la surface, p.ex. au moyen de masques
C23C 16/04 - Revêtement de parties déterminées de la surface, p.ex. au moyen de masques
C23C 18/16 - Revêtement chimique par décomposition soit de composés liquides, soit de solutions des composés constituant le revêtement, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement; Dépôt par contact par réduction ou par substitution, p.ex. dépôt sans courant électrique
in vivoin vivoin vivo neuron maturation/differentiation and/or vagus nerve modulation by administering a therapeutic amount of a composition comprising IGF-1, for example in a complex with an IGF-1 binding protein, such as IBGBP-3.
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with complementary inverse electron demand Diels-Alder cycloaddition reactivity, which upon ligation, followed by oxidation, will form compounds of a single isomeric form. The labeled single isomeric chemical entity targeting vectors are for use in therapy, radiotherapy, theranostics, diagnostics, and imaging. The method applies click chemistry wherein one chemical entity which is conjugated to a label is clicked together with a second chemical entity with complementary inverse electron demand Diels-Alder cycloaddition reactivity which is conjugated to a targeting vector followed by a rapid oxidation, to form a single isomeric compound.
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
C07D 209/94 - Systèmes cycliques contenant au moins trois cycles condensés en [b, c] ou [b, d] contenant des carbocycles autres que des cycles à six chaînons
C07D 241/42 - Benzopyrazines avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone de l'hétérocycle
C07D 257/10 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 209/52 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle condensés avec un cycle autre qu'un cycle à six chaînons
The present disclosure relates to compounds which bind Ca2+/calmodulin dependent protein kinase II. It also relates to such compounds for use in the treatment of CNS disorders with sleep disturbances and acute brain injury.
C07D 277/06 - Composés hétérocycliques contenant des cycles thiazole-1, 3 ou thiazole-1, 3 hydrogénés non condensés avec d'autres cycles ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 277/12 - Composés hétérocycliques contenant des cycles thiazole-1, 3 ou thiazole-1, 3 hydrogénés non condensés avec d'autres cycles comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec des hétéro-atomes ou des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 277/56 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with complementary inverse electron demand Diels-Alder cycloaddition reactivity, which upon ligation, followed by oxidation, will form compounds of a single isomeric form. The labeled single isomeric chemical entity targeting vectors are for use in therapy, radiotherapy, theranostics, diagnostics, and imaging. The method applies click chemistry wherein one chemical entity which is conjugated to a label is clicked together with a second chemical entity with complementary inverse electron demand Diels-Alder cycloaddition reactivity which is conjugated to a targeting vector followed by a rapid oxidation, to form a single isomeric compound.
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
C07D 209/94 - Systèmes cycliques contenant au moins trois cycles condensés en [b, c] ou [b, d] contenant des carbocycles autres que des cycles à six chaînons
C07D 241/42 - Benzopyrazines avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone de l'hétérocycle
C07D 257/10 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 209/52 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle condensés avec un cycle autre qu'un cycle à six chaînons
The present disclosure regards a qubit circuit comprising at least first and second data qubits and a mediator qubit coupling the first and second data qubits in a circuit plane, wherein the first data qubit and the second data qubit are coupled to the mediator qubit by means of respective twist couplers, each twist coupler comprising superconducting regions connected by superconducting transmission lines, wherein at least two of the connecting transmission lines cross each other at a line crossing point where the crossing transmission lines are separated by an insulator layer.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
According to the invention there is provided methods for making heparan sulfate with increased anticoagulant activity wherein the resulting product has a lower heterogeneity and presents an improved safety profile compared to conventional animal‐sourced heparin.
The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 27/00 - Médicaments pour traiter les troubles des sens
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
15.
HUMANIZED CHIMERAS FOR THE PROSPECTIVE ASSESSMENT OF CELL ADDITION AND REPLACEMENT THERAPIES
A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and/or (2) at least 5% of all of the glial cells in the white matter of the brain and/or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.
The present invention relates to a method for preparing gold nanoparticles and nanomaterials without the need for organic adsorbates having a molar mass above 100 g/moL The present invention also relates to a colloidal dispersion of the gold nanoparticles obtained by the methods according to the invention, solid and redispersed nanomaterials and products comprising gold nanoparticles.
B22F 1/00 - Poudres métalliques; Traitement des poudres métalliques, p.ex. en vue de faciliter leur mise en œuvre ou d'améliorer leurs propriétés
B22F 9/16 - Fabrication des poudres métalliques ou de leurs suspensions; Appareils ou dispositifs spécialement adaptés à cet effet par un procédé chimique
B22F 1/0545 - Dispersions ou suspensions de particules de taille nanométrique
B22F 9/24 - Fabrication des poudres métalliques ou de leurs suspensions; Appareils ou dispositifs spécialement adaptés à cet effet par un procédé chimique avec réduction de mélanges métalliques à partir de mélanges métalliques liquides, p.ex. de solutions
17.
A METHOD OF MANIPULATING A QUBIT AND AN ASSEMBLY COMPRISING A QUBIT
An assembly comprising a qubit and a method of altering a qubit, where a presence of a charge in a storage element close to the qubit influences on the state in which the altering is performed. Then, altering may be performed by feeding signals to electrodes, where the same signal is fed to the qubit but where the state is altered only if the charge is present in the storage element. Multiple qubits may then receive the same signal and only the ones with a charge are altered by the signal.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
A circuit for transferring charge, which may be in the form of charged particles from a first storage element to one of a plurality of second storage elements, the circuit comprising a circuit element configured to receive the charge or charged particles and deliver the charge or charged particles to an identified one of the plurality of second storage elements. The charge delivered may be the same charged particles or other charged particles. The circuit may be used for embodying Boolean circuits or gates operable at cryo temperatures.
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
G06N 10/00 - Informatique quantique, c. à d. traitement de l’information fondé sur des phénomènes de mécanique quantique
H01L 27/18 - Dispositifs consistant en une pluralité de composants semi-conducteurs ou d'autres composants à l'état solide formés dans ou sur un substrat commun comprenant des composants présentant un effet de supraconductivité
The present invention relates to designed water for brewing of coffee. Specifically the designed water of the invention can be used to prepare good-tasting coffee.
A23F 5/24 - Extraction du café; Extraits de café; Fabrication du café instantané
A23F 5/26 - Extraction des constituants solubles dans l'eau
A23L 33/16 - Sels inorganiques, minéraux ou oligo-éléments
C02F 1/66 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par neutralisation; Ajustage du pH
C02F 1/68 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par addition de substances spécifiées, pour améliorer l'eau potable, p.ex. par addition d'oligo-éléments
20.
A METHOD FOR DETERMINING A CHARGE-STATE BOUNDARY OF A QUANTUM DOT, A MULTI-DOT DEVICE, OR AN ARRAY OF QUANTUM DOTS AND A DATA PROCESSING SYSTEM FOR PERFORMING THE METHOD
The invention regards a method for determining a charge-state boundary of a quantum dot, a multi-dot device, or an array of quantum dots, comprising the steps of defining an initial point inside a charge state of a quantum dot having a charge-state boundary, ramping gate voltages from the initial point thereby creating a plurality of rays in gate voltage space, creating a time stamp when each of the rays leave the charge-state / cross the charge-state boundary, and constructing the boundary of the charge state by correlating each ray in gate voltage space with the associated time stamp.
G01N 27/22 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la capacité
inter aliainter alia, to complexes of the Na+ leak channel non-selective protein (NALCN) with FAM155A (also called FAM155; Family with sequence similarity 155 member A), UNC79 (uncoordinated 79), and UNC80 (uncoordinated 80), methods of screening for molecules that modulate the activity of the complex, and identified modulators thereof.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
22.
ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP)
The present invention relates to humanized antibodies and molecular conjugates targeting Urokinase type plasminogen activator receptor associated protein (uPARAP), in particular antibody-drug conjugates (ADCs) comprising humanized antibodies directed against uPARAP and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as certain cancers.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
The invention concerns a compound of formula (I), a pharmaceutical formulation comprising the compound of formula (I) and use of the pharmaceutical composition for treating fibrotic, inflammatory, diabetic or cognitive disease.
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/4433 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'oxygène comme hétéro-atome du cycle
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 19/04 - Médicaments pour le traitement des troubles du squelette des troubles non-spécifiques du tissu conjonctif
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention relates to mutant Cas12j (also known as CasΦ) endonucleases having altered activity or improved properties compared to the corresponding wild type Cas12j endonuclease, as well as methods using the mutant Cas12j endonucleases.
The present invention relates to polypeptides derived from Ruminococcus torques, and polypeptide fragments and variants thereof useful for treatment and/or prevention of metabolic disorders, muscle disorders and injuries, and bone disorders, and host cells comprising said polypeptides, polypeptide fragments or variants thereof for use as a probiotic or as a Live Biopharmaceutical Product (LBP).
There are provided compositions and mucin-binding targeting agents derived from microbial proteins that have selective binding properties for densely glycosylated mucins as well as such compositions and targeting agents comprising a binding moiety and/or a payload which may be attached to the binding moiety or directly to a targeting agent. The compositions and targeting agents may be used as medicaments in the treatment of a disease, illness, or disorders.
C07K 14/32 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Bacillus (G)
C07K 14/33 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Clostridium (G)
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
The present invention relates to compounds capable of binding to the PDZ domains of PSD-95 and their medical use as inhibitors of protein-protein interaction mediated by PSD-95.
C07K 5/103 - Tétrapeptides la chaîne latérale du premier amino-acide étant acyclique, p.ex. Gly, Ala
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
C07K 5/113 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes carboxyle que de groupes amino, ou leurs dérivés, p.ex. Asp, Glu, Asn
A system (10, 21) for determining information relating to a first periodic signal, the system comprising a sequence of storage elements (12, 14) each configured to store at least one charged particle, where a signal with a constant voltage, V1 DC, V2 DC, and a signal with a varying voltage, V1 AC, V2 AC, is fed to each storage element. One of the signals with the varying voltage is the first periodic signal. By monitoring the current,I, pumped between the storage elements by the voltages applied to the storage elements, the information relating to the first periodic signal may be generated.
G01R 15/16 - Adaptations fournissant une isolation en tension ou en courant, p.ex. adaptations pour les réseaux à haute tension ou à courant fort utilisant des dispositifs capacitifs
30.
SMALL HYDROPHOBIC PROTEIN DRUG CONJUGATES AND USES THEREOF
The present disclosure provides peptide conjugated drugs based on MuV SH Protein, their use as therapeutic agents and their use to provide delivery to and/or transfer across a membrane of the drug. The present disclosure provides use of the peptide conjugated drug for delivery of the drug to and/or across a membrane harbouring G protein-coupled receptor 125 (GPR125), such as the choroid plexus.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A sensor for a cryogenic operated device, the set-up comprising dual quantum dots positioned so close to a conductor supplying an electrical signal to the device. A charged particle (32) in the quantum dots is affected and moved due to the field, so that detection of the position of the particle will provide information relating to the field and thus the signal.
The present disclosure relates to a method of manufacturing a transferable lamella comprising interconnected nanostructures, the method comprising the steps of: a)providing a substrate such as a planar substrate; b) forming at least one superstructure on the substrate, said superstructure comprising a plurality of elongated nanostructures (formed e.g. by growth, deposition, and/or etching); wherein the elongated nanostructures are formed such that at least two of said nanostructures are conductively interconnected, and/or wherein at least a first layer is grown or deposited to conductively interconnect or insulate at least a part of the elongated nanostructures; c) encapsulating at least a portion of said superstructure in an encapsulating material, said portion comprising at least two interconnected nanostructures; and d) cutting the encapsulating material in a direction that intersects at least two interconnected nanostructures, thereby manufacturing a transferable lamella comprising interconnected nanostructures. The present disclosure further relates to an electronic device manufactured from one or more of the lamellas provided by the method.
C30B 29/60 - Monocristaux ou matériaux polycristallins homogènes de structure déterminée caractérisés par leurs matériaux ou par leur forme caractérisés par la forme
H01L 39/22 - Dispositifs comportant une jonction de matériaux différents, p.ex. dispositifs à effet Josephson
H01L 29/66 - Types de dispositifs semi-conducteurs
NN2. Unfortunately, these structures display too low reactivity for in vivo bioorthogonal chemistry approaches. Highly reactive structures such as mono-unsubstituted tetrazines (H-Tzs) have been reported to be highly sensitive to base. Extensive degradation is observed which prevents isolation of meaningful amounts for imaging studies. In the present invention there is provided a method providing the possibility to radiolabel base sensitive tetrazine structures with significantly improved RCYs. Even tetrazines that were previously not accessible by applying "standard" aliphatic 18F-labeling strategies can be radiolabeled. This places new classes of 18F-fluorinated compounds within reach for application in PET imaginge studies such as for diagnosis of cancers.
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
The present invention relates to modular nanoparticle-based compositions based on nucleic acids, such as DNA and RNA, which are particularly useful in prophylaxis and/or treatment of diseases and disorders.
The present invention relates to mutated bacterial host cells, said host cells producing a polypeptide of interest and having at least one disrupted flagellum gene, and to nucleic acid constructs and vectors encoding at least one flagellum polypeptide with reduced or eliminated activity as well as to methods of producing one or more polypeptide of interest in said host cells.
C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p.ex. hyaluronidase, invertase, amylase
C07K 14/32 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Bacillus (G)
C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
The present disclosure relates to methods for assessing the effects of a mutation of interest in a cell. Herein are also disclosed systems for assessing the effects of a mutation of interest in a cell. The disclosure also provides host cells and host cell populations comprising the system.
The present invention concerns a method for site-selective modification of a target protein or peptide by use of an acylation tag comprising a single lysine residue and at least three histidine residues. Upon contact with an acylating reagent, the target protein or peptide becomes modified at the ε-amine of the lysine residue of the acylation tag.
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
C07K 1/107 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs
Disclosed herein are composite materials comprising amylose, cellulose nanofibres or cellulose nanocrystals, and a plasticiser. The amylose is of high purity, specifically containing little or no amylopectin. The cellulose nanofibres or cellulose nanocrystals act to reinforce the disclosed composite materials. Also disclosed are methods of producing such composite materials, and their use.
The present invention provides extracorporeal removal of targeting vectors applied in pretargeted therapy and diagnostics in animals and humans. The method and the means for extracorporeal removal of the targeting vectors is based on binding agents with inverse electron demand Diels-Alder (IEDDA) cycloaddition reactivity. The targeting vector comprises a therapeutic agent, a diagnostic agent or a theranostic agent and a chemical entity with IEDDA reactivity whereas the extracorporeal means comprises a column with a biocompatible solid support to which a chemical entity with complementary IEDDA reactivity is attached.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
The present invention relates to methods of modulating an activity of a Cas-effector on a target polynucleotide comprising contacting the Cas-effector with an inhibitor component, wherein the inhibitor component comprises an anti-CRISPR ribonucleotide sequence (acrRNA) capable of inhibiting the Cas-effector from (i) associating with a target nucleotide sequence; and/or (ii) associating with a CRISPR guide RNA, and thereby inhibiting the Cas-effector from forming an active RNA-guided Cas-effector complex.
The present invention relates novel cyclic peptides which can act as inhibitors of protein-protein interactions, specifically by inhibiting the PDZ2 domain of PSD-95, as well as their use in treatment of excitotoxic-related diseases and neuropathic pain.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
UNIVERSITY OF COPENHAGEN (Danemark)
Inventeur(s)
Feng, Yinnian
White, Adam K.
Hein, Jamin B.
Fordyce, Polly M.
Abrégé
The present disclosure provides methods, devices, systems and kits for producing polymeric microbeads, including lanthanide-encoded microbeads. Among others, the present disclosure provides methods, systems and kits for producing functionalized microbeads that include on their surfaces amphipathic moieties with free reactive groups that remain free and can be used for covalently coupling molecules or moieties of inters to the microbeads.
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Allemagne)
ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (Allemagne)
Inventeur(s)
Kjær, Andreas
Herth, Matthias Manfred
Jensen, Andreas Ingemann
Eder, Matthias
Eder, Ann-Christin
Abrégé
The present invention provides novel PSMA targeting urea-based ligands that binds to prostate‐specific membrane antigen (PSMA) which is expressed 8-to-12-fold higher in prostate cancer cells when compared to healthy tissue. The PSMA targeting urea-based ligands comprises a chelating agent that may comprise a metal and a halogen radioisotope of fluorine, iodine, bromine or astatine. The invention further relates to a method for providing the PSMA targeting urea-based ligands of the invention, to precursors of the PSMA targeting urea-based ligands and to the PSMA targeting urea-based ligands use in radiotherapy, imaging and theranostic.
The present invention relates to novel tetrazine compounds for use in pretargeted in vivo imaging and in therapy and to the precursors of the tetrazine compounds. The compounds are suitable for use in click chemistry, i.e. reactions that join a targeting molecule and a reporter molecule. The compounds comprise a radionuclide of F, I or At and on or more polar groups providing that the compounds can efficiently react with extracellularly located pretargeting vectors and as such used for example for pretargeted cancer diagnostics and cancer therapy.
The present disclosure is directed to systems for in vivo tracking of target cells resulting from implantation of a preparation of cells. The present disclosure is further directed to in vivo methods of tracking a preparation of cells implanted in a subject, and of preparations of cells.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
47.
A FLEXIBLE FOIL FOR THE DELIVERY OF THERAPEUTIC CARGOS
The present invention relates to a drug delivery platform. In particular, it relates to a foil-based drug delivery platform for delivery to the intestine.
The present invention relates to virally expressed peptides which bind to PDZ domains and thereby block PDZ domain mediated protein-protein interactions and expression vectors encoding these peptides. The virally expressed peptides comprise an oligomerization domain, capable of forming higher order constructs, such as trimers or tetramers, and a peptide ligand capable of binding to a PDZ domain. The invention furthermore relates to therapeutic use of said peptides and expression vectors encoding these peptides.
A61P 29/02 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS] sans effet anti-inflammatoire
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/00 - Préparations médicinales contenant des peptides
The present disclosure relates to a lipid conjugated bivalent peptide ligand which bind to Protein Interacting with C Kinase – 1 (PICK1) and thereby inhibit PICK1. The PICK1 inhibitors of the present disclosure comprise a peptide portion comprising two peptide ligands of PICK1, and a non-peptide portion comprising a linker, linking the two peptide ligands, and a lipid. The disclosure furthermore relates to therapeutic and diagnostic use of said PICK1 inhibitor for treatment of diseases or disorders associated with maladaptive plasticity.
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
50.
G PROTEIN-COUPLED RECEPTOR MODULATORS AND A PHARMACEUTICAL COMPOSITION
The invention concerns a compound of formula I, a pharmaceutical formulation comprising the compound of formula I and use of the pharmaceutical composition for treating inflammatory or diabetic disease.
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 31/44 - Pyridines non condensées; Leurs dérivés hydrogénés
Provided is a quantum computing device comprising a carbon nanotube, a superconducting substrate in quantum proximity to the nanotube and being in a superconducting state having a pairing correlation matrix with a substantial spin-triplet component in a direction perpendicular to the nanotube, and a magnet arranged to provide a longitudinal magnetic field along a longitudinal axis of the nanotube. Further provided is a quantum computing device comprising at least three substrates made of a superconductor material and each in a superconducting state, and a non- superconducting structure made of a material in which the electrons' closed trajectories experience strong spin-orbit coupling interactions and being in quantum proximity to the substrates. The sum of the phase differences between the order parameters of all of the substrates is at least π.
G06N 10/00 - Informatique quantique, c. à d. traitement de l’information fondé sur des phénomènes de mécanique quantique
H01L 39/12 - Dispositifs utilisant la supraconductivité ou l'hyperconductivité; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails caractérisés par le matériau
52.
POSITIVE ALLOSTERIC MODULATORS OF THE CALCIUM-SENSING RECEPTOR
The present invention relates to non-naturally occurring antibodies or active antibody fragments specifically binding the calcium-sensing receptor (CaSR), acting as positive allosteric modulators (PAMs) to provide for potent therapeutic agents. More particular, the immunoglobulin single variable domains (ISVDs) identified herein reveal a novel therapeutic strategy to reduce parathyroid hormone release in a subject, and are therefore suitable for treatment of hypercalcemia disorders. Moreover, co-application of such an ISVD and a synthetic PAM or calcimimetic results in a synergistic agonistic CaSR activity providing for pharmaceutical compositions as next generation CaSR drugs.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
The invention provides compounds of Formula (II) which comprise two terminal 2-aminoquinoline moieties. They are novel and potent inhibitors of the p47phox-p22phox protein-protein interaction that can inhibit the assembly and thus activation of the multisubunit and superoxide-generating NADPH oxidase 2 complex. The compounds are therapeutically relevant as they can reduce cell damage in diseases where NADPH oxidase 2 is a major contributor to generation of reactive oxygen species (ROS) and oxidative stress.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (France)
UNIVERSITE LAVAL (Canada)
GENTOFTE HOSPITAL (Danemark)
UNIVERSITY OF COPENHAGEN (Danemark)
Inventeur(s)
Petit, Marie-Agnès
Mathieu, Aurélie
Bisgaard, Hans
Shah, Shiraz
Nielsen, Dennis Sandris
Deng, Ling
Moineau, Sylvain
Dion, Moïra
Abrégé
Escherichia coliEscherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
The present disclosure relates to agonists of Tacr2, such as peptides agonist of Tacr2 and methods of using the same for treatment of insulin resistance, obesity and/or diabetes. The disclosure also relates to use of said agonists of Tacr2 for enhancement of energy consumption in an individual.
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
A61P 3/04 - Anorexigènes; Médicaments de l'obésité
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 5/50 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques pour augmenter ou potentialiser l'activité de l'insuline
The present disclosure relates to a method for defining epitaxial growth sites for growth of elongated nanostructures and a method for manufacturing elongated nanostructures based thereon. The present disclosure further relates to nanoscale devices, in particular devices based on forming an electrical connection to an elongated nanostructure. The presently disclosed methods can be utilized for manufacturing of elongated nanostructures as a part of a conventional routine for device processing. A first embodiment relates to a method for defining at least one epitaxial growth site on a growth substrate, comprising the steps of: providing a substantially planar substrate comprising at least one first structure with at least one first face for epitaxial growth, the first face forming a face angle, of at least 60°, to the planar substrate; providing a first shadow mask comprising at least one blocking layer accommodating at least one aperture for passage of catalyst particles through the blocking layer; and depositing catalyst particles at an incident angle with respect to the planar substrate, the incident angle chosen such that a catalyst particle deposited through an aperture of the blocking layer defines an epitaxial growth site on the first face.
C30B 29/60 - Monocristaux ou matériaux polycristallins homogènes de structure déterminée caractérisés par leurs matériaux ou par leur forme caractérisés par la forme
H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
The present invention relates to a method for promoting weight loss in an individual by matching the gut microbiota in said individual with a specific diet. More specifically, the present invention relates to a method for promoting weight loss in an individual having a high P/B ratio (a high relative abundance of Prevotella spp./Bacteroides spp.) in its microbiota by providing a diet rich in arabinoxylan oligosaccharides (AXOS) to said individual. The disclosure further relates to a method for promoting weight maintenance and/or reducing appetite in said individual.
A61K 31/702 - Oligosaccharides, c. à. d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61K 36/899 - Poaceae ou Gramineae (famille des céréales), p.ex. bambou, blé ou canne à sucre
A61P 3/04 - Anorexigènes; Médicaments de l'obésité
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
C12Q 1/04 - Détermination de la présence ou du type de micro-organisme; Emploi de milieux sélectifs pour tester des antibiotiques ou des bactéricides; Compositions à cet effet contenant un indicateur chimique
58.
COMPOSITIONS AND METHODS FOR PREDICTING AND PROMOTING WEIGHT LOSS IN PATIENTS WITH LOW AMY1 COPY NUMBERS
The invention provides methods for identifying biomarkers in a patient's microbiota to predict a patient's response to a predetermined diet to promote weight loss and methods of promoting weight loss or treating obesity in the patient by optimizing the patient's diet in accordance with the biomarkers identified in the patient's gut microbiota. The methods of the invention can also be used to manage or maintain weight, i.e., prevent or inhibit weight gain, in a patient who is of normal weight or is overweight or obese.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
A23L 33/00 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement
C12Q 1/40 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une hydrolase une amylase
C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p.ex. hyaluronidase, invertase, amylase
59.
USE OF FFAR2 AGONISTS FOR THE TREATMENT OF BACTERIAL SUPERINFECTIONS POST-VIRAL INFECTION
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (France)
UNIVERSITÉ DE LILLE (France)
INSTITUT PASTEUR DE LILLE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (France)
UNIVERSITY OF COPENHAGEN (Danemark)
Inventeur(s)
Trottein, François
Ulven, Trond
Sencio, Valentin
Abrégé
S. pneumoniaeS. pneumoniae. Lastly, the inventors showed that pharmacological manipulation of the FFAR2 agonist TUG-1375 provides the same benefit as acetate in the treatment of bacterial superinfection post-influenza. The present invention thus relates to the use of synthetic free fatty acid receptor 2 (FFAR2) agonist for the treatment of bacterial superinfections post-viral infection (e.g. post-influenza).
The present invention describes a uPAR-targeting peptide conjugate comprising a fluorophore, a peptide binding to uPAR and a linker group which are connected by covalent bonds, wherein the uPAR-targeting peptide conjugate may be used as fluorescence probe in real time optical imaging and delineation of cancer tumors or metastases during surgery.
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
A compound for use in the treatment of CNS disorders with sleep disturbances e.g. narcolepsy or Angelman syndrome in a subject, wherein said compound is according to formula (I) or any isomer, tautomer, enantiomer, racemic form or deuterated form thereof, or a pharmaceutically acceptable salt thereof.
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/235 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
62.
MIRTAZAPINE FOR USE IN MEDICATION OVERUSE HEADACHE BASED ON TENSION-TYPE HEADACHE
The present invention relates to the field of headache treatment. In particular, it relates to mirtazapine for use in the treatment and/or prophylaxis of medication overuse headache based on tension-type headache. Moreover, the present invention concerns a pharmaceutical composition comprising mirtazapine for use in the treatment of medication overuse headache based on tension-type headache.
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
A61K 31/616 - Acide salicylique; Ses dérivés ayant le groupe hydroxyle en position 2 estérifié, p.ex. acide salicylsulfurique par des acides carboxyliques, p.ex. acide acétylsalicylique
The present invention relates to cysteine derivatives for use in the treatment or prevention of a bacterial infection by inhibiting bacterial quorum sensing. Bacterial infections of particular interest are bacterial infections caused by Gram-positive bacteria that employ thiolactone containing auto-inducing peptides (AIPs).
A61K 31/145 - Amines, p.ex. amantadine ayant des atomes de soufre, p.ex. thiurames (N-C(S)-S-C(S)-N ou N-C(S)-S-S-C(S)-N); Sulfinylamines (-N=SO); Sulfonylamines (-N=SO2)
The present invention relates to vasodilators for use in the treatment of a retinal ischemic disorder in a mammal by reducing the retinal ischemic damage for both the photoreceptors (A-wave amplitude) and the Muller and ON-bipolar cells (B-wave amplitude) by at least 10%, when measured by Electroretinography in the mammal compared to the ET-1 induced ischemia alone, at day 3 and at day 21 after the ischemic event and the vasodilator is first applied. The vasodilator may preferably be selected from the group consisting of Calcitonin gene-related peptide (CGRP), amylin, adrenomedullin, and calcitonin.
The present invention relates to neuropeptide Y (NPY)-derived peptide fragments that bind to Neural Cell Adhesion Molecule (NCAM), for use in the treatment of cardiovascular diseases, in particular cardiac disease, such as cardiac diseases associated with arrhythmias, such as cardiac arrhythmia.
The present invention relates to the discovery and development of ago-allosteric modulators on the free fatty acid receptor 1 and their use in therapy, particularly their use in the treatment of diabetes.
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p.ex. chlorazanil, mélamine
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
A61K 31/4427 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
The present invention relates to peptides and peptide analogues with high affinity for the PDZ domains of PICK1. The peptide or peptide analogue interacts with PICK1, blocking the native protein-protein interactions between PICK1 and its natural ligands. The invention furthermore relates to the therapeutic use of these peptides and peptide analogues in prevention and/or treatment of diseases and disorders associated with maladaptive plasticity, drug addiction and neuropathic pain.
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
68.
VIRALLY EXPRESSED INHIBITORS OF PDZ DOMAINS, SUCH AS PICK1 AND USES THEREOF
The present invention relates to virally expressed peptides with high affinity for the PDZ domains, such as the PDZ domain of PICK1. The invention furthermore relates to the therapeutic use of these peptides in prevention and/or treatment of diseases and/or disorders associated with maladaptive plasticity and/or transmission.
The present invention relates to lysosomal enzymes modified by use of cell based methods, a compositions comprising a modified lysosomal enzyme, as well as methods for producing a modified lysosomal enzyme and therapeutic use of such modified lysosomal enzyme. In particular, the present disclosure relates to a modified lysosomal enzyme which has low Man6P and low exposed Mannose and high sialic acid content of alpha2,3 type enabling long circulation time and improved uptake into difficult-to-reach organs like heart, kidney and brain.
C12N 9/36 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons bêta-1, 4 de l'acide N-acétylmuramique avec l'acétylamino-2 déoxy-2-D-glucose, p.ex. lysozyme
An aerated food product, such as a mousse, whipped topping, ice cream and frozen desserts, comprising a fat component and sunflower wax as a structuring agent is disclosed. Also disclosed is a method of producing an aerated food product that contains oils which have a low content of saturated fatty acids.
The present disclosure further relates to nanostructures, in particular hybrid superconductor-semiconductor nanostructures with patterned growth of various layers for use in nanoscale electronic devices, such as hybrid superconductor-semiconductor nanostructures with patterned growth and/or deposition of superconducting material for use in quantum devices. The presently disclosed method can be utilized for in-situ manufacturing of nanoscale electronic devices that have not been contaminated by ex-situ processes. One embodiment relates to a method for manufacturing a substrate for growth of crystalline nanostructures, the method comprising the steps of: depositing one or more layers (2) of a epitaxial crystal growth compatible dielectric material, such as silicon oxide, in a predefined pattern on the surface of a epitaxial crystal growth compatible substrate (1) to create a predefined etch pattern of said epitaxial crystal growth compatible material, and selectively etching (Fig. 1C) the substrate surface around said etch pattern to provide at least one under-etched platform which is vertically raised from the etched substrate surface and depositing an electrically conducting material (3) on the top of the platform and on the substrate, such that owing to the under-etching the layers (3) on the platform and on the substrate are electrically isolated (Fig. 1D).
H01L 29/66 - Types de dispositifs semi-conducteurs
H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
H01L 39/22 - Dispositifs comportant une jonction de matériaux différents, p.ex. dispositifs à effet Josephson
H01L 39/24 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement des dispositifs couverts par ou de leurs parties constitutives
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
B82Y 40/00 - Fabrication ou traitement des nanostructures
There is provided novel polypeptide-based carrier systems, which make it possible to label polymeric nanoparticles in the living organism. This enables new approaches in tumor diagnostics (high signal to background ratio) and radiotherapy (radiotherapy of solid tumors). The polypeptide-based carrier system comprises a polypept(o)idic comb (graft) copolymer, and one or more tetrazine bioorthogonal functional groups each linked to a diagnostic agent.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p.ex. émulsion, microcapsules, liposomes
The disclosure herein relates generally to a method of treating or inhibiting onset of Huntington's disease. This method involves selecting a subject having or at risk of having Huntington's disease and administering to the subject one or modulators of one or more genes as described herein, or proteins encoded therefrom, under conditions effective to treat or inhibit onset of Huntington's disease in the subject.
The present disclosure is directed to methods of restoring glial cell K+uptake in a subject. This method involves selecting a subject having impaired glial cell K+uptake, and administering, to the selected subject, a RE1 -Silencing Transcription factor (REST) inhibitor under conditions effective to restore glial cell K+uptake. Subjects having impaired glial cell K+ uptake include those at risk of having or having a neuropsychiatric disease or disorder.
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p.ex. clozapine, dilazèpe
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
The present invention relates to mutant Cpf1 endonucleases having altered activity compared to the wild type Cpf1, and their use to introduce single strand breaks in nucleic acid sequences. Methods for detection and quantification of a nucleic acid sequence are also disclosed. Methods for diagnosis of an infectious disease are also disclosed.
The present invention relates to compositions comprising Fenofibrate for use in the treatment, prophylaxis and/or prevention of hypoglycaemia in type 1 diabetes or other related diseases in humans. This treatment, prophylaxis and/or prevention is particularly relevant for subjects that are genetically predisposed to these diseases. The daily dose ranges from 1-100 mg/kg bodyweight per day.
The present invention relates to a method for improving the clinical efficacy of adoptive T cell therapy with a MerTK ligand. The invention further relates to a MerTK ligand for use in the treatment of a cancer in an individual, wherein said method comprises 5 adoptive T cell therapy.
There is provided a synthesis of [18F]SFB (N-succinimidyl 4-[18F]fluorobenzoate) using a one-step reaction procedure without generating radioactive waste gases. [18F]SFB is useful as a reagent for labeling of low- and high-molecular weight compounds such as peptides and antibodies which can then be used for PET (Positron Emission Tomography) diagnostic studies.
C07D 407/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
C07D 207/46 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec les hétéro-atomes liés directement à l'atome d'azote du cycle
The present invention relates to polypeptides having myotoxin-neutralizing properties and their use for treatment of envenomation. The present invention further relates to methods for neutralizing a venom using the polypeptide of the invention as well as to methods of treatment of envenomation by administering said polypeptide to a subject in need thereof.
The present invention relates to compounds with high affinity for the PTB domain of Mint proteins. The compound interacts with Mint, blocking the native protein-protein interactions between Mint and their natural ligands. The invention furthermore relates to the therapeutic use of these compounds in prevention and/or treatment of neurodegenerative diseases, such as cognitive diseases, for example Alzheimer's disease, as well as to the use for diagnosing Alzheimer's disease.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
81.
METHOD AND SUBSTRATE FOR PATTERNED GROWTH ON NANOSCALE STRUCTURES
The present disclosure relates to a method for manufacturing of specially designed substrates for growth of nanostructures and patterned growth on said nanostructures. The present disclosure further relates to nanostructures, in particular hybrid semiconductor nanostructures with patterned growth of superconducting material for use in quantum devices. The presently disclosed method can be utilized for in-situ manufacturing of quantum devices that have not been contaminated by ex-situ processes.
H01L 39/22 - Dispositifs comportant une jonction de matériaux différents, p.ex. dispositifs à effet Josephson
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
B82Y 40/00 - Fabrication ou traitement des nanostructures
H01L 21/033 - Fabrication de masques sur des corps semi-conducteurs pour traitement photolithographique ultérieur, non prévue dans le groupe ou comportant des couches inorganiques
H01L 39/24 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement des dispositifs couverts par ou de leurs parties constitutives
H01L 29/66 - Types de dispositifs semi-conducteurs
H01L 29/775 - Transistors à effet de champ avec un canal à gaz de porteurs de charge à une dimension, p.ex. FET à fil quantique
H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
A subject's level of soluble urokinase type plasminogen activator (suPAR) is checked as part of a risk stratification procedure in a hospital emergency department to help decide whether to admit the subject to the hospital, keep the subject in as a patient, or discharge a patient.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
83.
COMPOSITE COMPRISING GREEN RUST AND CARBON FOR ENVIRONMENTAL REMEDIATION
The invention regards a composite for environmental remediation, comprising: - one or more green rust compound(s) or green rust precursor(s), and - one or more biochar(s).
The present invention relates to a peptide hormone with one or more O-glycans attached at specific amino acid residues as well as to formulations comprising the same.
NEDERLANDS INSTITUUT VOOR ECOLOGIE (NIOO-KNAW) (Pays‑Bas)
UNIVERSITY OF COPENHAGEN (Danemark)
Inventeur(s)
De Bruijn, Irene
Raaijmakers, Josephus Maria
Buchman, Kurt
Abrégé
The invention relates to the use of bacterial lipopeptide biosurfactants in the treatment of white spot disease in fresh water and marine fish. Particularly useful for treatment of white spot disease are viscosin-like lipopeptide biosurfactants obtainable from the Pseudomonas fluorescens strain H6, massetolide or a derivative thereof and putisolvin or a derivative thereof.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir d
A61K 38/02 - Peptides à nombre indéterminé d'amino-acides; Leurs dérivés
86.
COMBINATION THERAPY FOR TREATMENT OF BONE DISORDERS
Provided herewith is the use of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-2 (GLP-2) for treatment of bone disorders such as osteoporosis.
The present invention relates to companion diagnostics for colorectal cancer, in particular for prediction of benefit of topoisomerase 1 inhibitor-treatment, such as irinotecan treatment, based on the expression level of selected biomarkers.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
88.
SYSTEM FOR ELECTRICAL STIMULATION DURING FUNCTIONAL MRI
The present disclosure relates to a system for generating a predefined electrical signal in an MR scanner for use in electrical stimulation of a subject during MRI or functional MRI of said subject, wherein said MR scanner is located inside a shielded MRI room. The system comprises a control unit to be located outside the MRI room for generating an electrical signal and an electrical to optical converter to be located outside the MRI room for converting said electrical signal to a corresponding optical signal. An optical transmitting element, such as an optical fiber, is used for transmitting the optical signal into the MRI room, and an optical to electrical converter is used for converting the optical signal to said predefined electrical signal for electrical stimulation of the subject during magnetic resonance imaging. The optical to electrical converter is configured for being located inside the MRI room and for operation during magnetic resonance imaging.
A61N 1/08 - Aménagements ou circuits de surveillance, de protection, de commande ou d'indication
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
The present invention relates to peptides which are capable of potentiating the chemotactic potential of glycosaminoglycan binding chemokines, and to the use of said chemotaxis-potentiating peptides in the treatment of cancer.
A method for obtaining a betalain pigment composition from red beet plants comprising pre-harvest foliar spraying of an ethylene-generating compound and the use of the ob- tained betalain pigment composition for coloring of an edible product.
A23L 5/43 - Adjonction de colorants ou de pigments, p.ex. en combinaison avec des azurants optiques en utilisant des colorants ou des pigments organiques d'origine naturelle, leurs doublons artificiels ou leurs dérivés
C09B 61/00 - Colorants naturels préparés à partir de sources naturelles
The invention regards an wearable garment fabric for electric muscle stimulation (EMS) comprising: - an array of electrodes, wherein the electrodes are configured for multi-channel electromyography (EMG) and multi-channel EMS pulses, - an EMG control system configured for collecting EMG data within the electrode array when the fabric wearer makes a muscle(s) pose, and - an EMS control system configured for generating EMS pulses within the electrode array to replay the muscle(s) pose, wherein the EMS pulses are calibrated based on the collected and processed EMG data.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
92.
Method for controlling growth of microorganisms and/or biofilms in an industrial process
The invention relates to a method for controlling of a biofilm, for removing of a formed biofilm and/or for controlling a growth of microorganisms, preferably bacteria, in an aqueous environment of an industrial manufacturing process comprising cellulosic fibre material. In the method a composition comprising a compound selected from a group consisting of 3-[(4-methylphenyl)sulphonyl]-2- propenenitrile and 4-amino-N-2-thiazolyl-benzenesulphonamide is administered to the aqueous environment of the process.
Methods of preventing creaming and age gelation in heat treated dairy based products are provided herein. Heat treated dairy based products are also provided, in which physical instability is prevented.
A23L 3/00 - Conservation des aliments ou produits alimentaires, en général, p.ex. pasteurisation ou stérilisation, spécialement adaptée aux aliments ou produits alimentaires
A23G 1/48 - Produits à base de cacao, p.ex. chocolat; Leurs succédanés caractérisés par la composition contenant des végétaux ou des parties de ceux-ci, p.ex. des fruits, des graines, des extraits
A23G 1/56 - Produits liquides; Produits solides sous forme de poudre, de flocons ou de granules pour obtenir des produits liquides, p.ex. pour faire du lait au chocolat
A23L 29/206 - Aliments ou produits alimentaires contenant des additifs; Leur préparation ou leur traitement contenant des agents gélifiants ou épaississants d'origine végétale
A23L 29/238 - Aliments ou produits alimentaires contenant des additifs; Leur préparation ou leur traitement contenant des agents gélifiants ou épaississants d'origine végétale à partir de graines, p.ex. gomme de caroube ou gomme de guar
94.
TREATMENT OR PREVENTION OF GASTROINTESTINAL DYSBIOSIS
NORGES MILJØ-OG BIOVITENSKAPELIGE UNIVERSITET (NMBU) (Norvège)
SYKEHUSET ØSTFOLD HF (Norvège)
UNIVERSITY OF COPENHAGEN (Danemark)
Inventeur(s)
Lea, Tor
Kleiveland, Charlotte
Kristiansen, Karsten
Jensen, Benjamin Anderschou Holbech
Abrégé
Methylococcus capsulatusMethylococcus capsulatusMethylococcus capsulatusMethylococcus capsulatusMethylococcus capsulatusMethylococcus capsulatusMethylococcus capsulatus for use in said methods is further provided.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
95.
METHOD FOR GROWING SOMATIC EMBRYOS OF CONIFERS INTO TREES
AbiesAbies and to the use of plants thus obtained. The invention concerns a method for treating and growing somatic embryos under conditions that induce and stimulate root growth, that induce and stimulate shoot formation and increases the survival rate of the embryos, plantlets and emblings. The emblings can subsequently be grown into trees. Trees derived from somatic embryogenesis and grown according to the method of the invention are of a very homogeneous appearance and quality, which is preferred in the production of trees such as Christmas trees thereby reducing the wastage rate.
The present invention relates to genomic regions which are useful markers for determining whether a subject suffers from an inflammatory bowel disease, such as ulcerative colitis or Crohn's disease, or is healthy. Also disclosed are useful primers for measuring expression levels of said markers, as well as computer-implemented methods.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
C07K 14/415 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de végétaux
A01H 5/00 - Angiospermes, c. à d. plantes à fleurs, caractérisées par leurs parties végétales; Angiospermes caractérisées autrement que par leur taxonomie botanique
98.
COMPOSITIONS AND METHODS FOR PREDICTING AND PROMOTING WEIGHT LOSS
The invention provides methods for identifying biomarkers in a patient's microbiota to predict a patient's response to a predetermined diet to promote weight loss and methods of promoting weight loss in the patient by optimizing the patient's diet in accordance with the biomarkers identified in the patient's gut microbiota. The methods of the invention can also be used to manage or maintain weight, i.e., prevent or inhibit weight gain, in a patient who is of normal weight or is overweight or obese.
Disclosed are glucose-dependent insulinotropic peptide (GIP)-derived peptide analogues GIP5-30 and GIP3-30 which are antagonists of the GIP receptor and comprises at least one fatty acid molecule to increase half-life while maintaining antagonistic properties.
The present invention relates to a method for in vivo detection of the loss and/or presence of endothelial glycocalyx by using labelled microbubbles and ultrasound. The microbubbles are labelled with peptides via a lipid recognising specific components of the glycocalyx.